provides a mobile payments platform headquartered in San Francisco, CA, enabling consumers to pay for goods and services using their mobile phone number, with purchases billed to a consumer's mobile network operator bill.This form of mobile payment, also referred to as carrier billing, enables unbanked consumers who may have a mobile phone, but no credit card or traditional bank account, to make purchases online, as well as banked customers who simply find carrier billing a simpler way to transact.The majority of transactions processed through Boku carrier billing are for digital and virtual goods and services, including music streaming, online video, digital subscription services, mobile device app stores, social and free-to-play games, virtual goods, social networks and other online experiences.Boku focuses on making the mobile phone number a viable payment option not only for virtual goods, but for digital goods (i.e.MP3's, eBooks, movies, etc.)Boku’s vision is to make the mobile phone number the world’s easiest way to pay.

Contents 1 2 3 4 5 6 7 8 Originally called Vidicom Ltd, and founded in Chesterfield, Derbyshire, U.K.möbel spenden bonnin 2003 by Glyn Smith and Thomas Kirk, Vidicom Ltd sought funding from venture capitalists in Silicon Valley for its application "Mobillcash".roller möbel lieferung und aufbauVidicom Ltd incorporated Boku inc as a Delaware company in 2009 and reestablished itself as Boku.an und verkauf möbel nieskyBoku launched in the USA in 2009 with the acquisition of both Mobilcash and Paymo – a provider in the mobile payments industry – as well as $13 million USD in investment from venture capital firms.[1]möbelgeschäfte in chemnitz

A year later, Boku added $25 million USD in a series C round, led by DAG Ventures.[2]möbel boss mainz.deIn 2012, Boku raised another $35 million USD round to be used to continue building out its payments business globally, led by NEA and existing venture capital investors.[3]möbelhäuser magdeburg prospekteThe latest round, $13.75 million USD was completed in 2016 and led by a consortium of UK investors and GMO Payment Gateway to fund carrier connections for global expansion.[4]In total, Boku has raised more than $91M in venture capital funding from Benchmark Capital, Index Ventures, Khosla Ventures, DAG Ventures, Andreessen Horowitz, New Enterprise Associates, Telefónica, and GMO Payment Gateway.Boku is connected to more than 300 carriers and has launched in 60+ markets offering a bank grade payment system to the largest global companies.[5]

In November 2013, Boku announced the acquisition of Qubecell, India’s largest aggregator in carrier billing to grow India as its engineering and technology hub.[6]In 2015, Boku acquired Mobileview to strengthen its footprint in Italy,[7] and Germany-based Mopay, one of its biggest competitors.[8]As of September 2016, Boku has offices in San Francisco, US (Americas HQ), London, UK (EMEA headquarters), Singapore (APAC headquarters) and several other countries (India, Germany, France, China, Taiwan, Japan, Italy, Latvia, Brazil) Boku is the largest independent carrier billing company in the world.Its platform is used in all the leading digital marketplaces including Google Play Store, Sony PlayStation Store, Microsoft Windows Store, Facebook App Center, and Spotify.In addition, Boku has established partnerships with leading game publishers and online services., Bigpoint, Goodgame Studios among others.Leading payment service providers (Adyen, Ingenico, Optimal Payments, Xsolla,[9] and others) choose to offer Boku to their clients as alternative payment option.

Boku provides businesses with the ability to put charges on end users’ phone bill.While the original payment panel product is still in place, Boku has expanded its capabilities to credit card like functionalities like charge and refund to enable cross platform purchases.Enhanced features, such as phone on file or header enrichment, offer consumers and merchants a more convenient way to pay.[10]Boku also offers a subscription product, which gives merchants greater control and flexibility compared to existing market solutions.[11]In 2011, Mobile Trax awarded Boku their Mobility Award.[12]In 2011 [13] and 2013,[14] Forbes selected Boku for their 25 most promising companies in America list.In 2014, Boku won the “Best Alternative Payments” award at 2014 Payment Awards [15] ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^Friday, March 27, 2015 by: David Gutierrez, staff writerTags: genetic engineering, vaccines, genome Amish girl who fled United States to escape forced chemotherapy is now cancer-free Is the secret to “beast mode” as simple as fasting?

- The Amish, who don’t get vaccinated, rarely get autism, cancer, or heart disease - coincidence?- All signs point to a corporate takeover of the marijuana industry by Bayer, Monsanto What they won't tell you: The sun is a full-spectrum medicine that can heal cancer How antidepressants ruin your natural serotonin so you can never be happy again ... without your pills Study proves lemon eucalyptus essential oil is better mosquito repellent than DEET Depopulation test run?75% of children who received vaccines in Mexican town now dead or hospitalized REVEALED: Cancer industry profits 'locked in' by nagalase molecule injected into humans via vaccines... spurs tumor growth... explains aggressive vaccine push Question: what is trisodium phosphate and what is it doing in our food?

Successful marriage depends on husband's attitude: Research The best and worst forms of magnesium to take as a supplement The best and worst forms of magnesium to take as a supplement Pepsi admits its soda contains cancer-causing ingredients The 8 Most Dangerous Medicines on Earth... are you taking any of these?Top 9 vaccines you NEVER need and exactly why the CDC has to scare everybody into getting them Statin scam exposed: Cholesterol drugs cause rapid aging, brain damage and diabetes Hillary Clinton's health in rapid collapse... voters in shock after photos show her unable to walk up small flight of stairs Does green tea have caffeine?Seven things you need to know Hexavalent chromium (chromium-6) was just found in 75% of drinking water... the mass chemical suicide of America is under way Chaos will erupt across America in less than 100 days... no matter who wins the election Top six alkaline foods to eat every day for vibrant health 12 easy ways to remove acid build-up from your body, alkalize your pH and beat disease CLAIM: Historic event to occur in the next six days that will end the rise of Trump and seize the future of America for totalitarian globalists Hillary Clinton video: THE WALKING DEAD... collapses into security van... 'medical event'... diagnosed with 'vascular dementia' and Parkinson's... 'one year left to live' says doctor Ten home remedies for fever - Natural ways to reduce a high fever and treat the flu using simple products found in most homes 10 health benefits of cucumbers Dear Donald Trump: Blockade the lying mainstream media and recognize the independent media as America's real free press Kellogg's found to have financial ties to the money man for cop-killing left-wing HATE groups: George Soros (NaturalNews) Recently, scientists took a huge leap forward in developing a radically new form of immunization.

Researchers from the Scripps Research Institute reported in February that they had successfully used a new form of gene therapy to induce monkeys to produce an antibody that deactivates HIV.This new therapy is fundamentally different from vaccination, which consists of introducing small amounts of infectious material into the body to induce it to produce its own antibodies.In immunoprophylaxis by gene transfer (IGT), scientists instead hope to modify the DNA of patients to enable them to produce entirely new antibodies."Thereality is we are touching third rails, and so it's going to take some explanation," said David Baltimore of the California Institute of Technology, a Nobel Prize recipient, virologist and IGT researcher.Bypassing the immune system In IGT, scientists first identify the genes (in humans or other animals) that produce powerful antibodies against hard-to-treat diseases.They then create artificial versions of these genes and insert them into viruses.These viruses are then injected into patient (usually into muscle tissue), where they transfer the genetically engineered DNA to the muscle cells.

Although muscle cells normally do not produce antibodies, the viral DNA changes their genetic programming, and the muscles start producing the antibodies.The first major breakthrough in IGT came in 2009, when Philip R. Johnson of the University of Pennsylvania and colleagues announced that they had successfully used the technique to cause monkeys' muscles to produce antibodies that protected the animals from SIV, a version of HIV that affects nonhuman primates.In 2011, Baltimore and colleagues successfully used IGT to protect mice against injected HIV.In 2014, they were able to use the technique to protect female mice against HIV introduced vaginally."We'regoing around the immune system, rather than trying to stimulate the immune system," Baltimore said."So what we're doing is pretty fundamentally different from vaccination, although the end result is pretty similar."Scientistsare also researching the possibility of using IGT to confer resistance to many other diseases that have resisted vaccination, including malaria, respiratory diseases (such as cystic fibrosis, influenza or SARS) and even Ebola.Many technical hurdles remain before IGT therapies could be widely adopted, however.

Michael Farzan, lead author of the recent Scripps study, notes that scientists still need to figure out how to regulate the body's production of the new antibodies, or shut it off."Ifwe really want to see this blossom, we need regulatory 'off' switches," he said.Designer immune systems on the horizon?Although scientists and bioethicists claim that IGT is no different than existing gene therapies and is therefore not ethically problematic, they admit that the public may see things differently.The prospect of having one's DNA modified to fight a disease may not be easily accepted.As with all gene therapies, IGT also raises concerns about the ethical implications of gene therapies designed to "improve" or "enhance" human beings rather than simply treat medical conditions.Conferring disease immunity arguably straddles the line between these approaches.Injecting viruses that are designed to modify the human genome also carries the risk of potentially severe side effects.Thus far, gene therapy researchers have mostly limited themselves to what is known as somatic gene therapy, rather than germ line gene therapy.

In the former, only non-reproductive DNA is modified, meaning that the modified traits cannot be passed on to future generations.It is widely accepted that germ line gene therapy poses an even more perilous ethical landscape than the gene therapies already under development.Finally, the prospect of modifying the human genome raises the question, as always, of who would control such technology, and who would get to decide when it would be used.(Natural////GMO_Dangers,_opinion is the new search engine for truth seekers.Follow real-time breaking news headlines on Genetic engineering at FETCH.news The world of independent media, all in one place.Your privacy is protected.Unsubscribe at any time.More news on genetic engineering First GMO ever produced by genetic engineering poisoned thousands of AmericansThe globalization of GMOs: How genetic engineering is destroying the developing worldBiotech industry pushing genetically engineered crops that they insist aren't genetically engineeredScientists now attempting to 'rewild' crops through genetic engineering in order to pass them off as organicGenetic engineering technology now spearheading the return of eugenics and the push for a 'master' superior race of menBreeding technique allows farmers to conventionally breed plants based on genetic markers; GMOs are unnecessary, costly, dangerous and now obsoleteGMOs are dangerous to our health, according to latest independent research Take Action: Support Natural News by linking to this article from your website Permalink to this article: /049148_genetic_engineering_vaccines_genome.html Embed article link: (copy HTML code below): New GMO vaccines alter human DNA to produce artificial immunity Reprinting this article: with clickable link.